The Technological Vanguard of Molecular Surveillance

adicionou um novo artigo Health

2026-01-23 08:58:38 -

The Minimal Residual Disease Testing Market Technology in 2026 is defined by a shift toward ultra-sensitive whole-genome sequencing (WGS) and digital PCR (dPCR) platforms. These innovations have pushed the limits of detection to a staggering 1 in 10 million cells, allowing oncologists to identify traces of cancer that were previously "invisible" even to standard NGS. A major breakthrough...

0 Comentários 0 Compartilhamentos 1K Visualizações 0 Anterior